The thrombopoietin receptor, MPL, associates with JAK2 and TYK2 to activate several signal transduction pathways to control blood cell development. Simple variants in MPL are seen in about 2% of all tumors, including 3% of skin tumors. Preclinical studies suggest that MPL mutations may be targeted with JAK2 inhibitors.